Actavis PLC (ACT.N)

ACT.N on New York Stock Exchange

254.20USD
24 Dec 2014
Price Change (% chg)

$-1.68 (-0.66%)
Prev Close
$255.88
Open
$256.28
Day's High
$258.45
Day's Low
$254.07
Volume
164,321
Avg. Vol
468,025
52-wk High
$272.75
52-wk Low
$164.02

ACT.N

Chart for ACT.N

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.31
Market Cap (Mil.): $67,378.54
Shares Outstanding (Mil.): 265.06
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): -- 38.24 38.63
EPS (TTM): -4.18 -- --
ROI: -3.50 19.00 18.26
ROE: -6.36 19.75 19.13
Search Stocks

FDA denies approval for Actavis hypertension treatment

- Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan.

24 Dec 2014

CORRECTED- FDA denies approval for Actavis hypertension treatment

Dec 24 - Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan.

24 Dec 2014

Actavis, Adamas win FDA approval for Alzheimer's drug

- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.

24 Dec 2014

Actavis, Adamas win FDA approval for Alzheimer's drug

Dec 24 - The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.

24 Dec 2014

Exclusive: Express Scripts presses for expansion of drugs it won't cover

LOS ANGELES - Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.

23 Dec 2014

Express Scripts presses for more drug savings with coverage list

LOS ANGELES - Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.

23 Dec 2014

Exclusive: Express Scripts presses for more drug savings with coverage list

LOS ANGELES - Express Scripts , the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.

23 Dec 2014

Spain's Almirall gains on report of Actavis interest

Dec 19 - Shares in Spanish drugmaker Almirall jumped 9 percent on Friday after a Bloomberg report of potential takeover interest from Actavis.

19 Dec 2014

UPDATE 1-U.S. judge says Actavis must keep selling Alzheimer drug

Dec 11 - A U.S. judge said in a preliminary injunction on Thursday that Actavis Plc must continue to sell its Alzheimer's drug after a lawsuit alleged the company was trying to limit generic competition while it launched an extended-release version of the widely used medicine.

11 Dec 2014

U.S. judge rules Actavis must continue to sell Alzheimer's drug

- A U.S. judge ruled on Thursday that Actavis Plc must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug.

11 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks